Levetiracetam for the treatment of hot flashes: a phase II study

Thompson, Susan; Bardia, Aditya; Tan, Angelina D.; Barton, Debra L.; Kottschade, Lisa A.; Sloan, Jeff A.; Christensen, Brad; Smith, Deanne; Loprinzi, Charles L.

doi:10.1007/s00520-007-0276-1

Cited by 9 publications

(3 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past two decades, investigators at Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) have conducted 13 pilot trials 17–28 as well as another 8 randomized trials evaluating the efficacy of various non-estrogenic agents for hot flashes. 29–36 Twelve of the pilot studies 17–28 and six of the randomized trials 29,30,33–36 collected information on breast cancer history or tamoxifen use.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use

Bardia¹,

Novotny

Sloan

et al. 2009

Menopause

Self Cite

View full text Add to dashboard Cite

Objective Various nonestrogenic therapies have been found to be effective in mitigating hot flashes, but it has been unclear whether the efficacy varies by whether women have had breast cancer and/or were taking tamoxifen. Methods This study used data from Mayo Clinic/North Central Cancer Treatment Group clinical trials that evaluated the efficacy of any nonestrogenic agent for hot flashes and had information on breast cancer history or tamoxifen use. Statistically significant changes from the fourth treatment week versus the baseline week, using individual patient data, were assessed using Student’s t test. Results A total of 1,396 women from 20 hot flash studies were eligible for analysis. Overall, women without breast cancer had a similar percentage of baseline hot flash score at week 4, as did those with breast cancer (53% vs 50%, P = 0.92). Women who were not taking tamoxifen had a significantly lower percentage of hot flash score at week 4 as compared with those who used tamoxifen (54% vs 61%, P = 0.01). However, this was due to a higher reduction in hot flash scores in the placebo arms among women not receiving tamoxifen; the percentage reduction in hot flash scores at week 4 from baseline in the active therapy arms of the randomized placebo-controlled trials (ie, excluding placebo arms) was similar among the tamoxifen users and nonusers (difference in mean percentage reduction, 5.7; 95% CI, −1.76 to 13.16). Conclusions Some nonestrogenic therapies seem to be useful for reducing hot flashes, irrespective of the etiology of hot flashes.

show abstract

Section: Methodsmentioning

confidence: 99%

“…29–36 Twelve of the pilot studies 17–28 and six of the randomized trials 29,30,33–36 collected information on breast cancer history or tamoxifen use. All of the trials had similar study methodology, including design and measurement tools, which have been validated both theoretically and empirically.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use

Bardia¹,

Novotny

Sloan

et al. 2009

Menopause

Self Cite

View full text Add to dashboard Cite

show abstract

“…Levetiracetam is not effective for neuropathic pain 20 or social anxiety disorder. 21 Benefit for bipolar disorder and hot flushes is reported, 4,22,23 but has not been confirmed in an RCT.…”

mentioning

confidence: 99%